UBS Remains a Hold on Elanco Animal Health (ELAN)

By Carrie Williams

In a report released today, Navin Jacob from UBS maintained a Hold rating on Elanco Animal Health (ELANResearch Report), with a price target of $28.00. The company’s shares closed last Monday at $26.65, close to its 52-week low of $25.25.

According to, Jacob is a 3-star analyst with an average return of 7.7% and a 50.0% success rate. Jacob covers the Healthcare sector, focusing on stocks such as Bristol Myers, Allergan, and Pfizer.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elanco Animal Health with a $31.20 average price target, representing a 19.0% upside. In a report issued on November 6, Craig-Hallum also maintained a Hold rating on the stock with a $30.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $35.46 and a one-year low of $25.25. Currently, Elanco Animal Health has an average volume of 4.18M.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELAN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.